Warnex | GenomeWeb

Warnex

NEW YORK (GenomeWeb News) – Luminex's board of directors has authorized the firm to repurchase up to the lesser of $22.5 million worth or 900,000 shares of the company's outstanding common stock. The repurchase program is scheduled to expire Dec.

NEW YORK (GenomeWeb News) – Warnex announced today a binding agreement to sell its Bioanalytical Services division to contract research organization Biotrial Research for C$6 million (US$6 million).

NEW YORK (GenomeWeb News) – Warnex today said that it has signed a new credit facility with Persistence Capital Partners, replacing an existing credit facility with Accord Financial.

NEW YORK (GenomeWeb News) – Warnex today announced it has completed the sale of its Analytical Services division to Neopharm Labs.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Warnex said this week that the conversion of debentures into shares of the company will provide Persistence Capital Partners with a nearly 52 percent stake in the firm.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Warnex today said that it has inked an agreement with an unnamed private company to purchase Warnex's Analytical Services division for more than C$1.1 million (US$1.1 million).

Pages

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.